Trial · NCT03659916
Results by group356
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 356
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Serum Bile Acids | Cohort 1: Placebo/Odevixibat | -104.00 | Standard Deviation 167.318 | micromole per liter (µmol/L) | |
| Change From Baseline in Serum Bile Acids | Cohort 1: Odevixibat/Odevixibat | -139.84 | Standard Deviation 172.070 | micromole per liter (µmol/L) | |
| Change From Baseline in Serum Bile Acids | Cohort 2: Odevixibat | -57.97 | Standard Deviation 137.990 | micromole per liter (µmol/L) | |
| Proportion of Positive Pruritus Assessments at the Participant Level Over 72-Week Using the Albireo Observer-Reported Outcome (ObsRo) Instrument | Cohort 1: Placebo/Odevixibat | 55.20 | Standard Deviation 38.733 | proportion of pruritus-participant-level | |
| Proportion of Positive Pruritus Assessments at the Participant Level Over 72-Week Using the Albireo Observer-Reported Outcome (ObsRo) Instrument | Cohort 1: Odevixibat/Odevixibat | 38.58 | Standard Deviation 34.877 | proportion of pruritus-participant-level | |
| Proportion of Positive Pruritus Assessments at the Participant Level Over 72-Week Using the Albireo Observer-Reported Outcome (ObsRo) Instrument | Cohort 2: Odevixibat | 77.28 | Standard Deviation 28.084 | proportion of pruritus-participant-level | |
| Proportion of Positive Pruritus Assessments at the Participant Level Using the Albireo ObsRo Instrument From Weeks 0-4, 0-12, 0-22, 0-24, 0-36, 0-46, 0-48, 0-60, and 0-70 | Cohort 1: Placebo/Odevixibat | Weeks 0 - 4 | 45.72 | Standard Deviation 34.300 | proportion of pruritus-participant-level |
| Proportion of Positive Pruritus Assessments at the Participant Level Using the Albireo ObsRo Instrument From Weeks 0-4, 0-12, 0-22, 0-24, 0-36, 0-46, 0-48, 0-60, and 0-70 | Cohort 1: Odevixibat/Odevixibat | Weeks 0 - 4 | 23.64 | Standard Deviation 27.005 | proportion of pruritus-participant-level |
| Proportion of Positive Pruritus Assessments at the Participant Level Using the Albireo ObsRo Instrument From Weeks 0-4, 0-12, 0-22, 0-24, 0-36, 0-46, 0-48, 0-60, and 0-70 | Cohort 2: Odevixibat | Weeks 0 - 4 | 60.14 | Standard Deviation 33.985 | proportion of pruritus-participant-level |
| Proportion of Positive Pruritus Assessments at the Participant Level Using the Albireo ObsRo Instrument From Weeks 0-4, 0-12, 0-22, 0-24, 0-36, 0-46, 0-48, 0-60, and 0-70 | Cohort 1: Placebo/Odevixibat | Weeks 0 - 12 | 51.05 | Standard Deviation 37.670 | proportion of pruritus-participant-level |
| Proportion of Positive Pruritus Assessments at the Participant Level Using the Albireo ObsRo Instrument From Weeks 0-4, 0-12, 0-22, 0-24, 0-36, 0-46, 0-48, 0-60, and 0-70 | Cohort 1: Odevixibat/Odevixibat | Weeks 0 - 12 | 27.34 | Standard Deviation 28.687 | proportion of pruritus-participant-level |
| Proportion of Positive Pruritus Assessments at the Participant Level Using the Albireo ObsRo Instrument From Weeks 0-4, 0-12, 0-22, 0-24, 0-36, 0-46, 0-48, 0-60, and 0-70 | Cohort 2: Odevixibat | Weeks 0 - 12 | 67.63 | Standard Deviation 33.645 | proportion of pruritus-participant-level |
| Proportion of Positive Pruritus Assessments at the Participant Level Using the Albireo ObsRo Instrument From Weeks 0-4, 0-12, 0-22, 0-24, 0-36, 0-46, 0-48, 0-60, and 0-70 | Cohort 1: Placebo/Odevixibat | Weeks 0 - 22 | 56.01 | Standard Deviation 38.537 | proportion of pruritus-participant-level |
| Proportion of Positive Pruritus Assessments at the Participant Level Using the Albireo ObsRo Instrument From Weeks 0-4, 0-12, 0-22, 0-24, 0-36, 0-46, 0-48, 0-60, and 0-70 | Cohort 1: Odevixibat/Odevixibat | Weeks 0 - 22 | 31.09 | Standard Deviation 31.859 | proportion of pruritus-participant-level |
| Proportion of Positive Pruritus Assessments at the Participant Level Using the Albireo ObsRo Instrument From Weeks 0-4, 0-12, 0-22, 0-24, 0-36, 0-46, 0-48, 0-60, and 0-70 | Cohort 2: Odevixibat | Weeks 0 - 22 | 70.05 | Standard Deviation 33.858 | proportion of pruritus-participant-level |
| Proportion of Positive Pruritus Assessments at the Participant Level Using the Albireo ObsRo Instrument From Weeks 0-4, 0-12, 0-22, 0-24, 0-36, 0-46, 0-48, 0-60, and 0-70 | Cohort 1: Placebo/Odevixibat | Weeks 0 - 24 | 56.00 | Standard Deviation 38.331 | proportion of pruritus-participant-level |
| Proportion of Positive Pruritus Assessments at the Participant Level Using the Albireo ObsRo Instrument From Weeks 0-4, 0-12, 0-22, 0-24, 0-36, 0-46, 0-48, 0-60, and 0-70 | Cohort 1: Odevixibat/Odevixibat | Weeks 0 - 24 | 31.45 | Standard Deviation 32.324 | proportion of pruritus-participant-level |
| Proportion of Positive Pruritus Assessments at the Participant Level Using the Albireo ObsRo Instrument From Weeks 0-4, 0-12, 0-22, 0-24, 0-36, 0-46, 0-48, 0-60, and 0-70 | Cohort 2: Odevixibat | Weeks 0 - 24 | 68.55 | Standard Deviation 34.116 | proportion of pruritus-participant-level |
| Proportion of Positive Pruritus Assessments at the Participant Level Using the Albireo ObsRo Instrument From Weeks 0-4, 0-12, 0-22, 0-24, 0-36, 0-46, 0-48, 0-60, and 0-70 | Cohort 1: Placebo/Odevixibat | Weeks 0 - 36 | 54.63 | Standard Deviation 38.243 | proportion of pruritus-participant-level |
| Proportion of Positive Pruritus Assessments at the Participant Level Using the Albireo ObsRo Instrument From Weeks 0-4, 0-12, 0-22, 0-24, 0-36, 0-46, 0-48, 0-60, and 0-70 | Cohort 1: Odevixibat/Odevixibat | Weeks 0 - 36 | 33.66 | Standard Deviation 33.704 | proportion of pruritus-participant-level |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03659916/results